

# GMP & Market Compliance Information Day September 27<sup>th</sup> 2012 The Crowne Plaza Hotel, Santry Demesne, Santry, Dublin 9

7:30	Registration

### 9.00 Welcome and Opening Address

## **Morning Programme**

Consisting of a short general forum session followed by the first parallel session after the coffee break

## 9:15 Introduction to Voting Pads

Some general instructions on use of the voting pads and collection of general information – e.g. what types of organizations are represented in the audience etc.

Facilitator: Cormac Dalton

## 9.30 Session 1: Regulatory update

**Speaker:** Paul Sexton

This session will include updates on GMP guidance and legislation

## 10:00 Session 2: Quality Management Considerations

Speaker: Chris Cullen

This session will include discussion of the use of ICH Q10 by manufacturers

### 10:30 Questions & Answers - Sessions 1 & 2

## 10:45 Morning Break - Tea/Coffee

## **Parallel Sessions**

The remainder of the programme will include parallel sessions covering specialist topics relevant to manufacture and market compliance. More parallel sessions have been incorporated to facilitate greater interaction. An overview of the specialist topics is provided below. Q&A will be incorporated into each parallel session. **Attendees may choose either session A or B.** 

### Choose Session 1A or 1B

44 45	Decellation of a 4.4	Carrier Carrell and a Chair Caller
11:15	Parallel Session 1A	Session Coordinator: Chris Cullen

## **Falsified Medicines Directive:**

This session will explore the practical implementation of those aspects of the FMD legislation which come into force in 2013.

Speaker	Title of Presentation
Chris Cullen	Falsified Medicines Directive
Anne Hayes	Starting Materials - Changes from FMD

### 11:15 Parallel Session 1B Session Coordinator: Lorraine Nolan

## **Improving Quality Risk Management Activities:**

Addressing the Problems of Subjectivity & Uncertainty

Speaker	Title of Presentation
Kevin O'Donnell	Improving Quality Risk Management activities to better support GMP Activities

### 12:30 Lunch Break



		Choose Session 2A or 2B
L4:00	Parallel Session 2A	Session Coordinator: Cormac Dalton
	Cleaning Validation – cha	Illenges old and new:
	Exploring traditional appr	oaches and new developments in this area
	Speaker	Title of Presentation
	Cormac Dalton	New Product Introduction and Assessing the Residues
	Victor Garvin	Cleaning Validation - Facility & Equipment Considerations & Potent Materials
	Sarah O'Meara	Cleaning Validation - The Toxicological Approach
4:00	Parallel Session 2B	Session Coordinator: Kevin O'Donnell
	Market Compliance Current Issues	
	Speaker	Title of Presentation
	Aoife Farrell	Quality Defects - Recent Trends
	Rob Smyth	Updates to the IMB Guide to Reporting of Quality Defects
	Kevin O'Donnell	Regulatory Compliance Inspections at MAH Offices - implications for manufacturers
:5:15	15 Minute Break - Change	eover Between Parallel Sessions
		Choose Session 3A or 3B
15:30	Parallel Session 3A	Session Coordinator: Greg McGurk
	Sterile and Biological Ma	
	_	current trends in deficiencies, environmental monitoring and the introduction of rapid
	microbiology methods.	current trends in deficiencies, environmental monitoring and the introduction of rapid
	Speaker	Title of Presentation
	•	Rapid Micro Methods
	(¬rea Mc(¬IIrk	
	Greg McGurk Denise Coakley	
	Denise Coakley	Deficiencies
	-	Deficiencies Environmental Monitoring
	Denise Coakley Paul Moody Gerard Sheridan	Deficiencies Environmental Monitoring Aseptic Process Validation
	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP)
	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance
15:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton
L5:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation – chal	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new:
5:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation – chal Exploring traditional appr	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: coaches and new development in this area.
15:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation - chal Exploring traditional appr Speaker	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: coaches and new development in this area. Title of Presentation
.5:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation – chal Exploring traditional appr	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: roaches and new development in this area. Title of Presentation Objectives and impact of the draft revision of the EMA PV guidance
5:30	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation - chal Exploring traditional appr Speaker Catherine McHugh Paul Sexton	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: coaches and new development in this area. Title of Presentation Objectives and impact of the draft revision of the EMA PV guidance Current GMP Guidance & revision of Annex 15
	Denise Coakley Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation - chal Exploring traditional appr Speaker Catherine McHugh	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: coaches and new development in this area. Title of Presentation Objectives and impact of the draft revision of the EMA PV guidance Current GMP Guidance & revision of Annex 15 Process Validation Deficiencies
L5:30 L6:45	Paul Moody Gerard Sheridan Gerard Sheridan Paul Moody  Parallel Session 3B  Process Validation — chal Exploring traditional appr Speaker Catherine McHugh Paul Sexton Kevin O'Donnell General Audience Feedba	Deficiencies Environmental Monitoring Aseptic Process Validation Steam in Place (SIP) Applicability of Annex 1 to manufacture of a Biological Drug Substance  Session Coordinator: Paul Sexton  lenges old and new: coaches and new development in this area. Title of Presentation Objectives and impact of the draft revision of the EMA PV guidance Current GMP Guidance & revision of Annex 15 Process Validation Deficiencies